• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Index insights
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Coronavirus
  • More reports can be found here

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Blogs » BioWorld MedTech Perspectives » Unapproved changes: Recent FDA warning letters

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Unapproved changes: Recent FDA warning letters

July 24, 2014
By Mark McCarty

David Bowie's changes: Would FDA have approved?
One of David Bowie's several ch-ch-changes: Would FDA have demanded a new 510(k)?

FDA’s warning letters to device makers serve as vehicles for all kinds of statements, including statements about when a device maker needs a new regulatory filing. Lately it seems that has come up a lot more, but is that a trend or just a blip on the screen?

We all remember the outcome of FDA’s confrontation with Steris in 2009. The agency hammered the firm for a series of incremental changes to its System 1 sterilizers, and Steris eventually caved, withdrawing the sterilizer and filing a new 510(k). Since then, the pressure on the 510(k) program has been constant, but not unchallenged. The agency had to withdraw its ill-advised 510(k) changes draft guidance, but that’s not the only means by which FDA can regulate changes to class II devices, is it?

In any event, a good example of this is the agency’s June 6 warning letter to CareFusion of San Diego.* The found itself in hot water over its handling of particulate matter found in some devices, but FDA also had problems with changes in the materials used for two sets of devices. What kind of changes? The letter isn’t very specific on that score.

The June 12 warning letter to Spinal Elements included a discussion of changes to the company’s Lucent series of intervertebral fusion devices, but the citation seems reasonable to the untutored eye. FDA said the company had added some “bulleted” designs and changed the angle of curvature by five degrees in some of these implants.

Another June warning letter, this one dated June 11 to Smith & Nephew, dealt with a change to the filter used in the company’s Renasys negative wound pressure therapy systems. The interesting thing here is that the company undertook the changes to correct a problem with the previous filter, and apparently it worked. The company’s June 23 statement indicates it is working with FDA on the agency’s demand that S&N cease distribution, so it doesn’t sound like the company will have much trouble persuading FDA this is no big deal.

In sum, it’s perhaps asking a lot to extrapolate from this to a shift in how FDA goes after changes to 510(k) devices, but let’s see what happens between now and the end of the year. After all, this is three warnings all dated in the month of June.

(Edit: Within hours of the time I posted this, FDA announced in the Federal Register the final version of a 2011 draft guidance dealing with evaluations of substantial equivalence.)

The difference between what and what?

I know FDA gets tired of me picking at it, but the warning to CareFusion mentioned above includes one of the more peculiar findings I’ve ever seen in a warning letter. The letter states that CareFusion’s procedures for the medical device reporting form, known as form 3500A, was incorrectly described in the firm’s documents as “FDA Form 3500A: MedWatch Medication and Device Experience Report.”

FDA said the correct descriptor is “MedWatch Form FDA 3500A Mandatory Reporting,” but it strikes me as odd that the agency would make a point of saying so in a warning letter. FDA has in the past made a fuss over terminology such as “reasonably became aware of” adverse events, and one can understand how that might be important. But the title of a form is a big enough deal to say something in a warning letter?

Granted a search engine does not return the exact same results in precisely the same order for these two terms, but seriously, someone at FDA needs to lighten up. This is ridiculous.

* The URL for the CareFusion warning will change June 29, when the letter moves from the set of newly posted warning letters to the agency’s warning letter archive.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 7, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for July 7, 2025.
  • U.S. Capitol building, Washington D.C.

    House passes H.R. 1, restoring R&D tax cuts

    BioWorld MedTech
    The House of Representatives passed H.R. 1, also known as One Big Beautiful Bill, which will restore personal income tax cuts that expired in 2022. However, the...
  • 3D rendering of a molecular glue mediating the interaction between two proteins

    With surface mimicry, molecular glues shed hairpin need

    BioWorld Science
    Degradation is a therapeutic strategy that could offer possibilities to get at currently undruggable target proteins. In targeted degradation, compounds induce...
  • Illustration of the β2-adrenergic receptor

    Exercise-mimicking compound offers alternative to GLP-1 therapies

    BioWorld
    An experimental drug for treating diabetes and obesity has been shown to lower blood sugar levels and increase fat burning. It is a β2-adrenergic receptor (β2AR)...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe